Agoracom Blog Home

Posts Tagged ‘CSE’

« Older Entries
Newer Entries »

Innocan $INNO.ca Moves to an Advanced Efficacy Trial on Animals of Its Liposome-CBD Injection, Following Encouraging Results on the First Stage $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 7:58 AM on Monday, November 16th, 2020
Innocan-Blog
  • Announced today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan’s CBD loaded liposome platform technology (“LPT”) in relevant diseases
  • These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection
  • The new studies will be conducted by the Hebrew University of Jerusalem

Herzliya, Israel and Calgary, Alberta–(November 16, 2020) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan’s CBD loaded liposome platform technology (“LPT”) in relevant diseases. These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection. The new studies will be conducted by the Hebrew University of Jerusalem.

The original study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Barenholz at the Hebrew University in Jerusalem found significant amounts of CBD in mices’ blood and muscles up to 21 days after they were injected intramuscular with a single injection of CBD using LPT. The same findings were also demonstrated in rats.

These results are substantial when compared to oral or smoking administration of CBD, in which CBD was found in the blood only for a period of up to 36 hours after one administration.

The results of this study may indicate that Innocan’s LPT, with an injection only once or twice a month, may relieve pain or other symptoms when using CBD. These results may open the door for future experiments to prove a lack of toxicity and therapeutic efficacy of this formulation.

Innocan Israel, a wholly owned subsidiary of Innocan, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company (“Yissum“), the commercial arm of the Hebrew University of Jerusalem in Israel, in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoid) loaded liposomes. The development is led by Prof. Chezy Barenholz, head of the Membrane and Liposome department at the Hebrew University, who invented over 55 patent families, two of which underlie Doxil – the first FDA approved nano-drug aim for cancer treatment. This LPT unique technology platform may be effective for several applications (such as epilepsy, pain relief, and different inflammation and central nervous system disorders). A patent was filed by Innocan Israel on the LPT technology on October 7, 2019.

Prof. Chezy Berenholz, head of the Laboratory of Membrane and Liposome Research of the Hebrew University stated: ” I believe that these additional animal and efficacy studies are extremely important and may result in a major milestone. This may open a wide range of clinical applications, while maintaining the CBD level in the blood for a long period of time which may lead to better patient compliance. If successful, the technology may be beneficial for various indications”.

About Innocan

The Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , , , , ,
Posted in Featured, Innocan Pharma Corporation | Comments Off on Innocan $INNO.ca Moves to an Advanced Efficacy Trial on Animals of Its Liposome-CBD Injection, Following Encouraging Results on the First Stage $CGC.ca $APHA $OVAT.ca $KHRN.ca

Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab Receives Record Order in Excess of $1,000,000 for COVID-19 Tests from Film and Television Production $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:52 AM on Monday, November 16th, 2020
  • Announced that Kai Medical Laboratory has received a record COVID-19 testing order that is anticipated to be in excess of $CAD 1,000,000
  • Today’s announcement represents a repeat and significantly higher purchase order of 9,000 RT-PCR tests to be processed over a four-month period by Kai Medical Laboratory.

VANCOUVER BC / November 16, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to announce that Kai Medical Laboratory (“KAI”) has received a record COVID-19 testing order that is anticipated to be in excess of $CAD 1,000,000.

9,000 TEST ORDER FOR FILM & TELEVISION PRODUCTION REPRESENTS REPEAT AND RECORD ORDER

In early October, shortly after the acquisition of KAI, Empower announced an agreement to process approximately 1,000 COVID-19 RT-PCR tests for a major film & TV production over a 30-day period, with the possibility of more business upon successful completion of the initial tests.

Today’s announcement represents a repeat and significantly higher purchase order of 9,000 RT-PCR tests to be processed over a four-month period by Kai Medical Laboratory. The total revenue from this order is anticipated to be in excess of $CAN 1,000,000.

Empower Clinics Chairman and CEO, Steven McAuley, stated “Just three days ago we were happy to inform our shareholders that KAI had achieved a record month in October with 1,375 units, as well as, signed numerous new commercial testing contracts, the details of which were to be provided in subsequent press releases. Today’s contract is not one of those contracts. We were informed of this contract at the close of business on Friday. As I said on Friday, the magnitude of KAI’s growth and success can not be overstated. Though we are very happy with today’s record order announcement, these 9,000 tests represent only a fraction of the lab’s capacity of 4,000 COVID-19 RT-PCR tests per day. It is our intention to build on this big success and continue ramping up growth significantly through 2020 and well into 2021.”

NEWLY ACQUIRED KAI MEDICAL LABORATORY HAS PROCESSED TESTS FOR SIX FILM AND TELEVISION PRODUCTIONS

As of September 1st, KAI has already processed tests for six different film and television productions in key US markets including Los Angeles, Atlanta, New York, Dallas and continues to build both confidence and credibility within the industry.

FILM AND TV STUDIOS SEEK FAST AND RELIABLE TESTING SOLUTIONS TO RESUME SAFE OPERATIONS AND MITIGATE BILLIONS IN LOSSES

Total earnings at the North American box office in 2019 amounted to $USD 11.32 billion indicated by Statistica.com. In January 2020, the U.S. motion picture and sound recording industry employed over 456 thousand people, with several hundred thousand more in Canada, U.K. and around the world.

As a result of production closures and cinema shutdowns related to COVID-19, the majority of the industry’s revenues and jobs have been temporarily lost and are now at significant risk of long-term damage, if the industry is unable to find solutions that can provide for the safe resumption of operations.

Specifically, the global film and television industry is projected to lose a staggering $160 billion of growth over the next five years, according to research firm Ampere Analysis.

On November 2nd, AMC Theatres announced a 91% drop in revenues during the most recent earnings period, with losses hitting $906 million in just one quarter.

Empower believes it is ideally positioned through Kai Medical Laboratory to deliver one element of the overall solution with reliable, accurate and fast 24-hour COVID-19 RT-PCR testing, which is the gold standard of testing.

KAI MEDICAL LAB GROWTH STRATEGIES & NEW COMMERCIAL TESTING CONTRACTS

The Company is now implementing aggressive growth strategies, including servicing new COVID-19 testing contracts for the film & television industry, as well as, supporting the Sun Valley Health COVID-19 RT-PCR and rapid antibody testing programs in the state of Arizona.

To this end, Empower has signed numerous new commercial testing contracts, the details of which will be provided in subsequent press releases.

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

The combination of all this commercial activity since the October 6th acquisition provides the Company with the confidence necessary to support the expectation of much further growth in the months to come.

COVID-19 RT-PCR TESTING IS THE GOLD STANDARD THAT ALLOWS EMPOWER TO ROLL OUT NATIONAL PHASE 4 TESTING PROGRAMS

KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab Receives Record Order in Excess of $1,000,000 for COVID-19 Tests from Film and Television Production $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

TransCanna $TCAN.ca Appoints Jennifer Brown as Director $VFF.ca $ACB.ca $CGC.ca $GTII.ca $TEQ.ca

Posted by AGORACOM-JC at 7:42 AM on Monday, November 16th, 2020
tcan-square
  • Announced the appointment of Ms. Jennifer Brown to the Company’s Board of Directors

Vancouver, British Columbia–(November 16, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company“) is pleased to announce the appointment of Ms. Jennifer Brown to the Company’s Board of Directors.

Ms. Brown is an Experienced Enterprise Risk Manager, Anti-Money Laundering, Compliance & Fraud Prevention Professional. Ms. Brown has over 15 years managing various organizations’ operations divisions and enterprise risk management programs at various financial institutions. In her roles, Ms. Brown has been responsible for the development and implementation of analytic fiscal reports, policies, and procedures that satisfy compliance requirements and maintaining thorough understanding of state and federal laws and regulations to ensure compliance. Mr. Brown earned a Bachelors’ Degree in Criminal Justice with concentration on Homeland Security from Brandman University and is currently pursuing an MBA in Accounting from National University. Ms. Brown is a member of the Association of Certified Anti-Money Laundering Specialist (ACAMS), California Financial Crimes Investigators Association (CFCIA), Northern California Compliance Roundtable, Sacramento Metro EDGE, and Sacramento Young Professionals (YP).

Ms. Brown has also been appointed a member of the Company’s audit committee.

“We are excited to have Jennifer join the Board of Directors here at Transcanna. She is a great addition to our team and brings a wealth of experience and knowledge to help propel the Company forward,” stated Bob Blink, the Company’s CEO.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Tags: , , , , , , , ,
Posted in TransCanna Holdings Inc. | Comments Off on TransCanna $TCAN.ca Appoints Jennifer Brown as Director $VFF.ca $ACB.ca $CGC.ca $GTII.ca $TEQ.ca

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Presenting at The Virtual Fall Investor Summit $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 7:38 AM on Monday, November 16th, 2020
kontrol-logo

TORONTO, ON / November 16, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) today announced that CEO Paul Ghezzi will present to investors at the Virtual Fall Investor Summit on Wednesday, November 18, 2020 at 4:00pm EDT. Participants can listen to Kontrol’s presentation at https://www.webcaster4.com/Webcast/Page/2038/38778. As facilitated by the conference, Kontrol will also participate in scheduled meetings.

“Kontrol Energy continues to build upon our base business that addresses the growing problem of energy waste, greenhouse gas emissions and air quality in the building sector,” said Mr. Ghezzi. “Kontrol has recently announced its plans to commercialize the Kontrol BioCloud analyzer (or BioCloud). BioCloud is a real-time viral detection technology. We look forward to connecting with the Virtual Fall Summit community.”

About Kontrol BioCloud

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.

Kontrol BioCloud is not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE:KNR) (OTCQB:KNRLF) (FSE:1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at http://www.sedar.com.

For further information, contact:

Paul Ghezzi, Chief Executive Officer [email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

About the Fall Investor Summit Conference

The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company: please contact Brittney Blocker ([email protected])

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

FOR MORE INFORMATION

Please visit: www.investorsummitgroup.com

Or, contact Brittney Blocker at [email protected]

News Compliments of ACCESSWIRE

SOURCE: Kontrol Energy Corp.

Tags: , , , , , , , , , ,
Posted in Kontrol Energy Corp. | Comments Off on Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Presenting at The Virtual Fall Investor Summit $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

FansUnite Entertainment Inc $FANS.ca $FUNFF Announces Uplist to Trade on the OTCQB Market $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

Posted by AGORACOM-JC at 7:29 AM on Monday, November 16th, 2020
  • Announced it has received approval to officially “uplist” from the Pink® market to the OTCQB Venture Market
  • The common shares will trade under the symbol FUNFF effective as of the opening of the market on November 16, 2020.

Vancouver, British Columbia–(November 16, 2020) – FansUnite Entertainment Inc (CSE: FANS) (OTCQB: FUNFF) (“FansUnite” or the “Company”), a sports and entertainment company, focusing on its technology related to regulated online sports betting and related products, is pleased to announce it has received approval to officially “uplist” from the Pink® market to the OTCQB Venture Market (“OTCQB”). The common shares will trade under the symbol FUNFF effective as of the opening of the market on November 16, 2020.

“We have seen an increased interest from American investors as the online betting space gains traction worldwide,” said Scott Burton, CEO of FansUnite Entertainment. “By upgrading our ticker, we will have increased visibility and exposure to a broader investment community. As we continue to execute on our vision of becoming a global iGaming leader, we are excited to showcase our achievements to a growing base of U.S. and international investors.”

The OTCQB is a Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on https://www.otcmarkets.com.

The move of FansUnite’s shares from Pink Market to OTCQB will not impact or require additional action from shareholders. The stock continues to trade on OTC but now will be accessible through the middle-tier OTC offering. In addition, there will be no change of trading under the Canadian Securities Exchange symbol FANS.

About FansUnite Entertainment Inc.

FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, Chameleon Gaming Platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high-growth potential in new or developing markets.

For further information, please contact:

Prit Singh Investor Relations at FansUnite
[email protected]
(905) 510-7636

Scott Burton Chief Executive Officer of FansUnite
[email protected]

Darius Eghdami President of FansUnite
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute “forward-‎looking information” under Canadian securities legislation. Generally, forward-looking information can be ‎identified by the use of forward-looking terminology such as “believes,” “belief,” “expects,” “intends,” ‎‎”anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or similar expressions to be uncertain ‎and forward-looking. Forward-looking statements may include, without limitation, statements relating to ‎future outlook and anticipated events such as:; ‎increased visibility and exposure resulting from trading on the OTCQB; ‎growth of the Company’s base of US and international investors;‎ the ‎Company’s unique portfolio of assets; and discussion of future plans, projections, objectives, estimates ‎and forecasts and the timing related thereto. Forward-looking statements are based on the Company’s ‎estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the ‎actual results, level of activity, performance or achievements of FansUnite to be materially different from ‎those expressed or implied by such forward-looking statements or forward-looking information. Additional ‎information regarding the risks and uncertainties relating to the Company’s business are contained under ‎the heading “Risk Factors” in the Company’s Non-Offering Prospectus dated March 27, 2020 filed on its ‎issuer profile on SEDAR at www.sedar.com and risks related to global pandemics, including the novel ‎coronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence ‎of macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking ‎statements and forward-looking information. The forward-looking statements in this news release are made ‎as of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-‎looking statements or forward-looking information, whether as a result of new information, future events or ‎otherwise, except as required by applicable securities laws.‎

Tags: , , , , , , , , , , , , ,
Posted in FansUnite Entertainment Inc., Featured | Comments Off on FansUnite Entertainment Inc $FANS.ca $FUNFF Announces Uplist to Trade on the OTCQB Market $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

VIDEO – Empower Clinics $CBDT.ca $EPWCF Sets Record At NEW Testing Lab AND Says Much More To Come $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 8:25 PM on Sunday, November 15th, 2020

Sometimes, you just have to let the numbers speak for themselves.  With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for … but then you see these numbers for the first half of the year:

Revenues $USD 1.7M vs $745,000 = 130% Gain

Patient Visits 12,400 vs 5,500 = 125% Gain

CBDT has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.

But he is far from done.

Earlier today Empower announced it’s fresh out of the oven, newly acquired Kai Medical Laboratory Achieved Record Testing Volume Month in October and Has Already Signed Numerous New Contracts

Despite officially acquiring KAI on October 5th, Empower was able to walk right into KAI and increase testing volume by 763% sequentially (vs September) to 1,375 units.  While most companies need a couple of months to really start making changes within the operations of new acquisitions, McAuley hit the ground running and even.

How much revenue was generated from these record October tests? CEO McAuley gives us back of the napkin math to play with.

But he is far from done.

Just as Empower did with their clinics, Empower has aggressive growth strategies in place for KAI, including servicing new COVID-19 testing contracts for the:

  • Film & television industry
  • Banks
  • Restaurants
  • Tourism and …. 
  • Supporting the Sun Valley Health COVID-19 RT-PCR and rapid antibody testing programs in the state of Arizona.

One, some or all of these should lead to even bigger numbers in November.  In fact, we asked him if he was “concerned” that he may run out of capacity of 4,000 tests per day (a great concern to have). Wait until you hear his answer.

But just one more thing

Empower announced it:

“has signed numerous new commercial testing contracts, the details of which will be provided in subsequent press releases.”

Somebody get out a calculator

It doesn’t take much to see that KAI has the potential to take Empower to a whole new level.  Specifically, if you’re an investor in Well Health (WELL:TSX) and/or CloudMD (DOC:TSXV) you have to start taking a serious look at Empower as the next great potential health and wellness company.  It’s already proven solid revenues and growth from its clinics, is expanding its telemedicine practice very nicely and now has the power to quickly generate significant enterprise level revenues from its newly acquired KAI medical diagnostics laboratory … which is already bearing fruit just 30 days after the acquisition.

Can McAuley pull it off?  First consider what he has already accomplished after inheriting a catastrophe of a company in early 2019.  Secondly, McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth through Q2 2020. 

And if you MISSED Well Health and CloudMD, you really need to take a close look at Empower as the next great potential small cap health & wellness company.

Watch this amazing interview.

Tags: , , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Empower Clinics Inc. | Comments Off on VIDEO – Empower Clinics $CBDT.ca $EPWCF Sets Record At NEW Testing Lab AND Says Much More To Come $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

VIDEO – Peak Fintech $PKK.ca $PKKFF CEO Johnson Joseph and ThreeD Capital $IDK.ca CEO Sheldon Inwentash, Discuss First Transaction Into 60,000 Store Marketplace – “You Ain’t Seen Nothing Yet” $ALY.ca $DELX.ca $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca

Posted by AGORACOM-JC at 8:22 PM on Sunday, November 15th, 2020
Peak Fintech Group (@PEAK_Fintech) | Twitter

How do you connect over 100M small businesses in China who need access to different kinds of credit …. with over 10K banks and lending institutions that have different lending criteria?

Well, if you try to do it the old fashioned way, you just can’t.  SMB’s (small and medium businesses) and Lenders are pretty much forced to deal within local markets which drastically reduces alternatives and business …. and both sides are left with a daunting, slow and inefficient manual workload. 

ENTER PEAK FINTECH

The Peak Fintech Lending Hub uses Artificial Intelligence and analytics to fully automate the process by which lenders and borrowers connect quickly and match perfectly across several market verticals.

When Joseph and Inwentash say this AI-Powered platform is revolutionizing the Chinese SMB commercial lending ecosystem, they’re not just paying lip service … Peak Fintech is delivering results

  • Reported revenue growth of 293% to $11.2 million for the first half of 2020
  • Targeting $40 million in revenues and $4 million in EBITDA for the 2020 year.
  • Platform now has lending products from 54 different banks and lending institutions
  • Signed Agreement To Bring Lending Hub To 60,000 Online Electronics Stores
  • Stores would use Lending HUB to finance purchase of electronics inventory
  • 100% market capture would translate into $1.35B in annual revenues 

Inwentash discusses what attracted him to PKK, what his interest is in the Company and what he sees for the Company’s future.

Joseph also discusses new government regulations in China since the Ant IPO was suspended and whether they would impact PKK, as well as, the Company’s growth outlook for 2021.  

Watch this great interview!

Tags: , , , , , , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Peak Fintech Group, Peak Positioning Technologies Inc. | Comments Off on VIDEO – Peak Fintech $PKK.ca $PKKFF CEO Johnson Joseph and ThreeD Capital $IDK.ca CEO Sheldon Inwentash, Discuss First Transaction Into 60,000 Store Marketplace – “You Ain’t Seen Nothing Yet” $ALY.ca $DELX.ca $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca

VIDEO – PlantX Life $VEGA.ca Goes Into Overdrive With Plant-Based Food and EVERYTHING, With Expansion In USA, UK and Europe $BYND $TSN $CAG $FMCI $VERY $MEAT

Posted by AGORACOM-JC at 7:00 PM on Sunday, November 15th, 2020
PlantX | LinkedIn

The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.

PlantX (VEGA:CSE) Is The One Stop Shop For Everything Plant Based + The  Digital Face of The Plant -Based Community with the following:

  • Plant Based Meal Delivery (20 meals)
  • Plant Based Snack Products
  • Plant Based Pet foods
  • Plant Based Restaurant Locator
  • Plant Based Recipes
  • Plant Based Essentials …. Like Chocolate (Essential?  You Bet)
  • And …… Plant Based …. PLANTS (It’s A BIG Business!)

More than just talk, VEGA is already in full swing and growing FAST

  • Already Operating In Canada
  • US Online Operations Kick Off With $USD 25M MIN of PlantX products YEAR 1
    • 6% Royalty Fee to PlantX on gross USA revenues
  • US Bricks & Mortar with San Diego flagship store opening in DECEMBER
  • Agreement already signed with a major construction company to build the flagship + franchises across North America
  • AND ….. The recent £8 million Acquisition of Bloombox In The UK, generating millions in revenue

If you believe in the paradigm shifting nature of plant based foods and more, be sure to watch and share this great interview with PlantX CEO Julia Frank.

Tags: , , , , , , , , , ,
Posted in AGORACOM Via Satellite, Featured, PlantX Life Inc. | Comments Off on VIDEO – PlantX Life $VEGA.ca Goes Into Overdrive With Plant-Based Food and EVERYTHING, With Expansion In USA, UK and Europe $BYND $TSN $CAG $FMCI $VERY $MEAT

Avicanna $AVCN.ca $AVCNF Announces Pricing of Public Marketed Offering of Units $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 12:05 PM on Friday, November 13th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Company intends to issue the Units at a price of $0.85 per Unit for gross proceeds of a minimum of $5,000,000 and a maximum of $7,000,000 . Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant
  • Each Warrant will be exercisable for one Common Share at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering.

TORONTO , Nov. 13, 2020 – Avicanna Inc. (” Avicanna “, or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that it has priced its previously announced marketed public offering (the ” Offering “) of units (the ” Units “) of the Company. The Company intends to issue the Units at a price of $0.85 per Unit for gross proceeds of a minimum of $5,000,000 and a maximum of $7,000,000 . Each Unit will consist of one common share of the Company (each a ” Common Share “) and one-half of one common share purchase warrant (each full warrant, a ” Warrant ” and collectively the ” Warrants “). Each Warrant will be exercisable for one Common Share (each a ” Warrant Share “) at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering.

The Offering is being conducted on a “best efforts” basis by a syndicate of agents led by Echelon Wealth Partners Inc., as lead agent and sole-bookrunner, and including Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the ” Agents “).

The Company has granted the Agents an option, exercisable in whole or in part, at the sole discretion of the Agents, at any time for a period of 30 days from and including the closing of the Offering, to purchase from the Company up to an additional 15% of the Units sold under the Offering, on the same terms and conditions of the Offering to cover over-allotments, if any, and for market stabilization purposes (the ” Over-Allotment Option “). The Over-Allotment Option may be exercised by the Agents to purchase additional Units, Common Shares, Warrants or any combination thereof.

The Offering will be completed on a “best efforts” basis through the Agents (i) by way of a short form prospectus to be filed in the Canadian Jurisdictions (ii) on a private placement basis to “accredited investors” meeting ‎one or more ‎of the ‎criteria in Rule 501(a) of ‎Regulation D (” Regulation D “) ‎under the United States Securities Act of 1933 , as amended (the ” U.S. Securities Act “) pursuant to Rule 506(b) ‎of Regulation D and/or ‎Section ‎‎‎4(a)(2) thereof and similar exemptions under ‎applicable state securities ‎‎laws, ‎Qualified Institutional ‎Buyers in the United States pursuant to the registration exemptions provided by Rule 144A of the US ‎Securities Act, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company’s securities under domestic or foreign securities laws.

The Offering is expected to close on or about December 3, 2020 , or such other date as the Company and the Agents may agree. Closing of the Offering is subject to customary closing conditions, including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals, including the approval of the securities regulatory authorities and the Toronto Stock Exchange.

The Company intends to use the net proceeds of the Offering for product development, working capital and general corporate purposes.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States . The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta , Colombia . Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020 , Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia .

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by the Company, including expectations and assumptions regarding the terms, timing and potential completion of the Offering, satisfaction of regulatory requirements in various jurisdictions and the use of proceeds from the Offering.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of manageme nt’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

Tags: , , , , , , , , ,
Posted in All Recent Posts, Avicanna Inc. | Comments Off on Avicanna $AVCN.ca $AVCNF Announces Pricing of Public Marketed Offering of Units $WEED.ca $TLRY $HARV.ca

AGORACOM Small Cap 60: FansUnite $FANS.ca $FUNFF Sets Monthly Gambling Record With 433% Increase Vs. Oct 2019 To $7.3 Million In Total Bets $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

Posted by AGORACOM-JC at 11:45 AM on Friday, November 13th, 2020

FansUnite Entertainment (FANS: CSE) (FUNFF:OTC) UK Sportsbook set company records with triple-digit growth in multiple areas, led by a 433% increase in overall revenue compared to October 2019 and a total Gross win of $602K CAD during the month. Much of the growth was attributed to McBookie’s live casino games and increased activity in sports betting which resulted in $7.3M in total betting volume being placed during the month.

Tags: , , , , , , , , , , , , ,
Posted in AGORACOM Small Cap 60, All Recent Posts, FansUnite Entertainment Inc. | Comments Off on AGORACOM Small Cap 60: FansUnite $FANS.ca $FUNFF Sets Monthly Gambling Record With 433% Increase Vs. Oct 2019 To $7.3 Million In Total Bets $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

« Older Entries
Newer Entries »